Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piatti, P.
Right arrow Articles by Alberti, K. G. M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piatti, P.
Right arrow Articles by Alberti, K. G. M.M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 24:875-880, 2001
© 2001 by the American Diabetes Association, Inc.


Emerging Treatments and Technologies
Original Article

Long-Term Oral L-Arginine Administration Improves Peripheral and Hepatic Insulin Sensitivity in Type 2 Diabetic Patients

PierMarco Piatti, MD1, Lucilla D. Monti, MD2, Gianpietro Valsecchi, PHD2, Fulvio Magni, MD3, Emanuela Setola, MD1, Federica Marchesi, MD2, Marzia Galli-Kienle, MD4, Guido Pozza, MD5 and K. George M.M. Alberti, FRCP5

1 Metabolic Diseases Unit
2 Medicine I Division
3 Mass-Spectrometry Unit Cattedra di Clinica Medica Generale e Terapia Medica, Università Vita-Salute, IRCCS H. San Raffaele
4 University of Milano-Bicocca, Faculty of Medicine, Milan, Italy
5 Department of Diabetes and Metabolism, School of Clinical Medical Sciences, University of Newcastle, Newcastle upon Tyne, U.K.

OBJECTIVE—The aim of this study was to evaluate whether long-term administration of L-arginine acting through a normalization of NO/cyclic-guanosine-3',5'-cyclic monophosphate (cGMP) pathway was able to ameliorate peripheral and hepatic insulin sensitivity in 12 lean type 2 diabetic patients.

RESEARCH DESIGN AND METHODS—A double-blind study was performed for 3 months. In the first month, patients were treated with their usual diet. Then they were randomly allocated into two groups. In group 1, patients were treated with diet plus placebo (orally three times per day) for 2 months. In group 2 patients were treated for 1 month with diet plus placebo (orally, three times per day) and then for 1 month with diet plus L-arginine (3 g three times per day). At the end of the first and the second month of therapy, patients underwent a euglycemic-hyperinsulinemic clamp combined with [6,6-2H2]glucose infusion. A total of 10 normal subjects underwent the same test as control subjects.

RESULTS—In group 1, no changes in basal cGMP levels, systolic blood pressure, forearm blood flow, glucose disposal, and endogenous glucose production were observed throughout. In group 2, L-arginine normalized basal cGMP levels and significantly increased forearm blood flow by 36% and glucose disposal during the clamp by 34%, whereas it decreased systolic blood pressure and endogenous glucose production by 14 and 29%, respectively. However, compared with normal subjects, L-arginine treatment was not able to completely overcome the defect in glucose disposal.

CONCLUSIONSL-Arginine treatment significantly improves but does not completely normalize peripheral and hepatic insulin sensitivity in type 2 diabetic patients.

Abbreviations: cGMP, cyclic-guanosine-3',5'-cyclic monophosphate • CV, coefficient of variation • NO, nitric oxide • NOS, NO synthase


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
V. Ouellet, J. Marois, S. J. Weisnagel, and H. Jacques
Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women: A randomized controlled trial
Diabetes Care, November 1, 2007; 30(11): 2816 - 2821.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
K. Krzyzanowska, F. Mittermayer, M. Wolzt, and G. Schernthaner
Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 Diabetes
Diabetes Care, July 1, 2007; 30(7): 1834 - 1839.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. Lucotti, E. Setola, L. D. Monti, E. Galluccio, S. Costa, E. P. Sandoli, I. Fermo, G. Rabaiotti, R. Gatti, and P. Piatti
Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E906 - E912.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. D. Monti, E. Setola, G. Fragasso, R. P. Camisasca, P. Lucotti, E. Galluccio, A. Origgi, A. Margonato, and P. Piatti
Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E54 - E59.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
G. K. McConell, N. N. Huynh, R. S. Lee-Young, B. J. Canny, and G. D. Wadley
L-Arginine infusion increases glucose clearance during prolonged exercise in humans
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E60 - E66.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Nystrom, A. Nygren, and A. Sjoholm
Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease
Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E919 - E925.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
N. Gokce
L-Arginine and Hypertension
J. Nutr., October 1, 2004; 134(10): 2807S - 2811S.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. Wilmore
Enteral and Parenteral Arginine Supplementation to Improve Medical Outcomes in Hospitalized Patients
J. Nutr., October 1, 2004; 134(10): 2863S - 2867S.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. D. Monti, C. Landoni, E. Setola, E. Galluccio, P. Lucotti, E. P. Sandoli, A. Origgi, G. Lucignani, P. Piatti, and F. Fazio
Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1225 - H1231.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. C Gannon, J. A Nuttall, and F. Q Nuttall
Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal
Am. J. Clinical Nutrition, November 1, 2002; 76(5): 1016 - 1022.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Coll. Nutr.Home page
N. T. Huynh and J. A. Tayek
Oral Arginine Reduces Systemic Blood Pressure in Type 2 Diabetes: Its Potential Role in Nitric Oxide Generation
J. Am. Coll. Nutr., October 1, 2002; 21(5): 422 - 427.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.